NO20076187L - Fast, transdermalt, terapeutisk system omfattende UV-absorber - Google Patents

Fast, transdermalt, terapeutisk system omfattende UV-absorber

Info

Publication number
NO20076187L
NO20076187L NO20076187A NO20076187A NO20076187L NO 20076187 L NO20076187 L NO 20076187L NO 20076187 A NO20076187 A NO 20076187A NO 20076187 A NO20076187 A NO 20076187A NO 20076187 L NO20076187 L NO 20076187L
Authority
NO
Norway
Prior art keywords
absorber
therapeutic system
layer
transdermal therapeutic
tts
Prior art date
Application number
NO20076187A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Langguth
Stefan Bracht
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20076187L publication Critical patent/NO20076187L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20076187A 2005-05-02 2007-11-30 Fast, transdermalt, terapeutisk system omfattende UV-absorber NO20076187L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05009579A EP1719504A1 (de) 2005-05-02 2005-05-02 Festes transdermales therapeutisches System mit UV-Absorber
PCT/EP2006/003959 WO2006117139A2 (de) 2005-05-02 2006-04-28 Festes transdermales therapeutisches system mit uv-absorber

Publications (1)

Publication Number Publication Date
NO20076187L true NO20076187L (no) 2007-11-30

Family

ID=34981458

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076187A NO20076187L (no) 2005-05-02 2007-11-30 Fast, transdermalt, terapeutisk system omfattende UV-absorber

Country Status (26)

Country Link
EP (2) EP1719504A1 (pt)
JP (2) JP5360877B2 (pt)
KR (2) KR101351161B1 (pt)
CN (2) CN108969507A (pt)
AR (1) AR055927A1 (pt)
AU (1) AU2006243442A1 (pt)
BR (1) BRPI0611087A2 (pt)
CA (1) CA2605112C (pt)
CR (1) CR9483A (pt)
CY (1) CY1115757T1 (pt)
DK (1) DK1879560T3 (pt)
DO (1) DOP2006000100A (pt)
EA (1) EA200702344A1 (pt)
ES (1) ES2523663T3 (pt)
GT (1) GT200600183A (pt)
IL (1) IL186945A0 (pt)
MX (1) MX2007013779A (pt)
NO (1) NO20076187L (pt)
PE (1) PE20061414A1 (pt)
PL (1) PL1879560T3 (pt)
PT (1) PT1879560E (pt)
SI (1) SI1879560T1 (pt)
TW (1) TW200719902A (pt)
UY (1) UY29511A1 (pt)
WO (1) WO2006117139A2 (pt)
ZA (1) ZA200710418B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073696A1 (de) 2003-02-21 2004-09-02 Schering Ag Uv-stabiles transdermales pflaster
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
SI2613772T1 (sl) * 2010-09-06 2017-03-31 Bayer Intellectual Property Gmbh Transdermalni obliži z nizkim odmerkom z visoko stopnjo sproščanja zdravila

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
ES2081458T3 (es) * 1990-03-30 1996-03-16 Ciba Geigy Ag Composicion de pintura.
US8173592B1 (en) * 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
PT1269999E (pt) 2000-03-17 2013-06-11 Hisamitsu Pharmaceutical Co Penso com blindagem aos ultravioletas
EP1452173A1 (de) * 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
WO2004073696A1 (de) * 2003-02-21 2004-09-02 Schering Ag Uv-stabiles transdermales pflaster
KR101133459B1 (ko) * 2003-09-11 2012-04-12 시바 홀딩 인크 헤테로상 중합 기술로 제조한 광 안정화제의 농축된 수계 생성물

Also Published As

Publication number Publication date
MX2007013779A (es) 2008-01-22
PL1879560T3 (pl) 2015-02-27
UY29511A1 (es) 2006-08-31
AR055927A1 (es) 2007-09-12
ES2523663T3 (es) 2014-11-28
IL186945A0 (en) 2008-02-09
KR20130099203A (ko) 2013-09-05
PE20061414A1 (es) 2007-01-26
CY1115757T1 (el) 2017-01-25
EP1879560B1 (de) 2014-08-27
JP2013177451A (ja) 2013-09-09
CN101171001A (zh) 2008-04-30
ZA200710418B (en) 2009-08-26
TW200719902A (en) 2007-06-01
KR20080003854A (ko) 2008-01-08
CR9483A (es) 2008-01-21
CA2605112C (en) 2013-11-05
CN108969507A (zh) 2018-12-11
KR101351161B1 (ko) 2014-01-14
PT1879560E (pt) 2014-11-19
JP2008540352A (ja) 2008-11-20
EP1719504A1 (de) 2006-11-08
GT200600183A (es) 2007-01-03
JP5360877B2 (ja) 2013-12-04
EA200702344A1 (ru) 2008-12-30
WO2006117139A2 (de) 2006-11-09
AU2006243442A1 (en) 2006-11-09
KR101426218B1 (ko) 2014-08-05
EP1879560A2 (de) 2008-01-23
CA2605112A1 (en) 2006-11-09
WO2006117139A3 (de) 2007-04-19
DK1879560T3 (en) 2014-11-24
DOP2006000100A (es) 2007-01-31
SI1879560T1 (sl) 2015-01-30
BRPI0611087A2 (pt) 2010-08-03

Similar Documents

Publication Publication Date Title
First et al. The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression
EP4196113A1 (en) Pharmaceutical compositions and methods for treating parkinson's disease
Yan et al. Dural afferents express acid-sensing ion channels: a role for decreased meningeal pH in migraine headache
Argyropoulos et al. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder
Oliveira et al. The antidepressant-like effect of physical activity on a voluntary running wheel
First et al. The effects of reboxetine treatment on depression-like behavior, brain neurotrophins, and ERK expression in rats exposed to chronic mild stress
AR097045A2 (es) Sistema terapéutico transdérmico
HRP20050828B1 (hr) Uv-stabilni transdermalni flaster
BR0212026A (pt) Sistema terapêutico transdérmico com fentanila ou substâncias análogas
NO20076187L (no) Fast, transdermalt, terapeutisk system omfattende UV-absorber
JP2008517934A5 (pt)
Gomora et al. Mibefradil potently blocks ATP-activated K+ channels in adrenal cells
US20080233180A1 (en) Transdermal Patch and Method For Delivery Of Vitamin B12
Hadgraft et al. Passive transdermal drug delivery systems: recent considerations and advances
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
Zhang et al. Synaptophysin and the dopaminergic system in hippocampus are involved in the protective effect of rutin against trimethyltin-induced learning and memory impairment
Poretti et al. Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression
Liu et al. Potent inhibition of native TREK-1 K+ channels by selected dihydropyridine Ca2+ channel antagonists
Miyagishi et al. Cytoprotective effects of Hangekobokuto against corticosterone-induced cell death in HT22 cells
CL2013000709A1 (es) Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10).
WO2024018420A1 (en) Continuous delivery systems comprising a cannabinoid and medicinal uses thereof
Hanon et al. Prevention of dementia and cerebroprotection with antihypertensive drugs
WO2009007334A3 (de) Transdermale therapeutische systeme, welche den wirkstoff anastrozol enthalten
Hondebrink et al. High concentrations of MDMA (‘ecstasy’) and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells
TH87440A (th) ระบบรักษาโรคผ่านทางผิวหนังชนิดของแข็งที่มีสารดูดกลืนยูวี

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application